fda novavax - Search News

Order byBest matchMost fresh

FDA, Novavax and Covid-19 vaccine

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who hav...

STAT · 19h

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

· 2d

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

MIT Technology Review · 1d

The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.

Covid vaccines will soon be required to go through more rigorous trials to ensure that they really are beneficial for people who aren’t at high risk.

· 8h

Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot

Arizona PBS · 18h

FDA ends routine COVID shots for healthy young Americans

· 1d

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 20h

COVID shots should target newer strains of JN.1 variant, US FDA advisers say

· 1d

With vaccine approval process set to change, FDA advisers leave wiggle room in annual Covid-19 shot recommendations

FDA advisers recommend updating COVID shots to JN.1 strain

Moderna (MRNA), and Novavax (NVAX) agree as the FDA advisors recommend targeting JN.1 strain for updated COVID vaccines this fall. Read more here.

1don MSN

Trump’s FDA just changed COVID vaccine rules for 2025 — will you still qualify for boosters under the new guidelines?

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and high-risk individuals. While the FDA met to decide if vaccine formulas should change for fall 2025,

4don MSN

RFK Jr. pledged not to upend US vaccine system, but big changes are underway

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.